共 50 条
- [1] FIRST LINE SUNITINIB IN TYPE I AND II PAPILLARY RENAL CELL CARCINOMA (PRCC): SUPAP- A PHASE II STUDY OF THE FRENCH GENITO-URINARY GROUP (GETUG) AND THE GROUP OF EARLY PHASE TRIALS (GEP)ANNALS OF ONCOLOGY, 2012, 23 : 263 - 263Ravaud, A.Oudard, S.De Fromont, M.Chevreau, C.Gravis, G.Zanetta, S.Theodore, C.Jimenez, M.Sevin, E.Escudier, B.
- [2] First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)ANNALS OF ONCOLOGY, 2015, 26 (06) : 1123 - 1128Ravaud, A.Oudard, S.De Fromont, M.Chevreau, C.Gravis, G.Zanetta, S.Theodore, C.Jimenez, M.Sevin, E.Laguerre, B.Rolland, F.Ouali, M.Culine, S.Escudier, B.
- [3] Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Plimack, E. R.Jonasch, E.Bekele, B. N.Qiao, W.Ng, C. S.Tannir, N. M.
- [4] Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Bjarnason, Georg A.Knox, Jennifer J.Kollmannsberger, Christian K.Soulieres, DenisErnst, D. ScottCanil, Christina M.Winquist, EricZalewski, PawelHotte, Sebastien J.North, Scott A.Heng, Daniel Yick ChinMacfarlane, Robyn JaneVenner, Peter M.Tannock, IanKapoor, AnilEigl, Bernhard J.Hansen, Aaron RichardCzaykowski, PiotrBoyd, BenBasappa, Naveen S.
- [5] Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales)EUROPEAN JOURNAL OF CANCER, 2021, 158 : 1 - 11Cancel, MathildeFromont, GaelleBlonz, CyriacChevreau, ChristineRioux-Leclercq, NathalieLaguerre, BrigitteOudard, StephaneGross-Goupil, MarineGravis, GwenaelleGoldwasser, FrancoisRolland, FredericDelva, RemyMoise, LauraEmambux, SheikVassal, CecileZanetta, SylviePenel, NicolasFlechon, AudeBarthelemy, PhilippeSaldana, CarolinaLefort, FelixEscudier, BernardLinassier, ClaudeAlbiges, Laurence
- [6] Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Pill, RobertoPal, Sumanta KumarGeorge, SabyVoortman, JensDanchalvijitr, PongwutAdelalye, RemiWebb, NancyPoslinski, DianeGroman, AdrienneHutson, AlanVerheul, Honk M. W.
- [7] Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Bjarnason, Georg A.Knox, Jennifer J.Kollmannsberger, Christian K.Soulieres, DenisErnst, D. ScottZalewski, PawelCanil, Christina M.Winquist, EricHotte, Sebastien J.North, Scott A.Heng, Daniel Yick ChinMacfarlane, Robyn JaneVenner, Peter M.Kapoor, AnilHansen, Aaron RichardEigl, Bernhard J.Czaykowski, PiotrBoyd, BenWang, LisaBasappa, Naveen S.
- [8] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical TrialONCOLOGIST, 2019, 24 (08): : E702 - E708Zhou, Ai-PingBai, YuxianSong, YanLuo, HongRen, Xiu-BaoWang, XiuwenShi, BenkangFu, ChengCheng, YingLiu, JiyanQin, ShukuiLi, JunLi, HanzhongBai, XianzhongYe, DingweiWang, JinwanMa, Jianhui
- [9] Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell CarcinomaONCOLOGIST, 2014, 19 (09): : 917 - 918Bellmunt, JoaquimSuarez, CristinaGallardo, EnriqueRodon, JordiPons, FrancescBonfill, TeresaBeltran, MartaMoya, IreneGaltes, SusanaAlbanell, JoanCarles, Joan
- [10] Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic dataANNALS OF ONCOLOGY, 2017, 28Bjarnason, G. A.Knox, J.Kollmannsberger, C. K.Soulieres, D.Ernst, D. S.Zalewski, P.Canil, C. M.Winquist, E.Hotte, S. J.North, S. A.Heng, D. Y. C.Macfarlane, R. J.Venner, P. M.Kapoor, A.Hansen, A. R.Czaykowski, P.Boyd, B.Wang, L.Basappa, N. S.